139
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Clinical Characteristics of Preterm Neonates with Aggressive Posterior Retinopathy of Prematurity

, , , ORCID Icon, , & ORCID Icon show all
Pages 2263-2277 | Published online: 01 Jun 2021

References

  • International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991–999. doi:10.1001/archopht.123.7.991
  • Holmstrom G, Broberger U, Thomassen P. Neonatal risk factors for retinopathy of prematurity– a population-based study. Acta Ophthalmol Scand. 1998;76(2):204–207. doi:10.1034/j.1600-0420.1998.760216.x
  • Shapiro M, Blair M, Gonzalez J. Aggressive posterior retinopathy of prematurity (APROP). In: Andrés Kychenthal B, Paola Dorta S, editors. Retinopathy of Prematurity. Cham: Springer International Publishing AG; 2017:49–70.
  • Gole G, Ells A, Katz X, et al. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123:991–999.
  • Vinekar A, Jayadev C, Mangalesh S, et al. Comparing the outcome of single versus multiple session laser photoablation of flat neovascularization in zone 1 aggressive posterior retinopathy of prematurity: a prospective randomized study. Retina. 2015;35(10):2130–2136. doi:10.1097/IAE.0000000000000604
  • Fierson W. American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2018;142(6):e20183061. doi:10.1542/peds.2018-3061
  • Good W; Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the early treatment for retinopathy of prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233–248.
  • Hussein M, Coats D, Khan H, et al. Evaluating the association of autonomic drug use to the development and severity of retinopathy of prematurity. J AAPOS. 2014;18(4):332–337. doi:10.1016/j.jaapos.2014.02.012
  • Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121. doi:10.1056/NEJMoa054065
  • Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–1902. doi:10.1056/NEJMoa073679
  • Lunt M, Ragab S, Birch A, et al. Comparison of caffeine-induced changes in cerebral blood flow and middle cerebral artery blood velocity shows that caffeine reduces middle cerebral artery diameter. Physiol Meas. 2004;25(2):467–474. doi:10.1088/0967-3334/25/2/006
  • Hoecker C, Nelle M, Beedgen B, et al. Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91(1):F61–F64. doi:10.1136/adc.2005.073866
  • Tracy MB, Klimek J, Hinder M, et al. Does caffeine impair cerebral oxygenation and blood flow velocity in preterm infants? Acta Paediatr. 2010;99(9):1319–1323. doi:10.1111/j.1651-2227.2010.01828.x
  • Kearns G, Abdel-Rahman S, Alander S, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–1167. doi:10.1056/NEJMra035092
  • Lotfi K, Grunwald J. The effect of caffeine on the human macular circulation. Invest Ophthalmol Vis Sci. 1991;32(12):3028–3032.
  • Terai N, Spoerl E, Pillunat L, et al. The effect of caffeine on retinal vessel diameter in young healthy subjects. Acta Ophthalmol. 2012;90(7):e524–e528. doi:10.1111/j.1755-3768.2012.02486.x
  • Darlow B, Hutchinson J, Henderson-Smart D, et al. Prenatal risk factors for severe retinopathy of prematurity among very preterm infants of the Australian and New Zealand neonatal network. Pediatrics. 2005;114(4):990–996. doi:10.1542/peds.2004-1309
  • Regev R, Lusky A, Dolfin T, et al. Excess mortality and morbidity among small for- gestational-age premature infants: a population-based study. J Pediatr. 2003;143(2):186–191. doi:10.1067/S0022-3476(03)00181-1
  • Sausgtad O. Update on oxygen free radical disease in neonatology. Curr Opin Obstet Gynecol. 2001;13(2):147–153. doi:10.1097/00001703-200104000-00009
  • Misra A, Heckford E, Curley A, et al. Do current retinopathy of prematurity screening guidelines miss the early development of pre-threshold type 1 ROP in small for gestational age neonates? Eye. 2008;22(6):825–829. doi:10.1038/sj.eye.6702728
  • Ahn Y, Hong K, Yum H, et al. Characteristic clinical features associated with aggressive posterior retinopathy of prematurity. Eye. 2017;31(6):924–930. doi:10.1038/eye.2017.18
  • Tolsma KW, Allred EN, Chen ML, et al. Neonatal bacteremia and retinopathy of prematurity: the ELGAN Study. Arch Ophthalmol. 2011;129(12):1555–1563. doi:10.1001/archophthalmol.2011.319
  • Abdel HA, Mohamed GB, Othman MF. Retinopathy of prematurity: a study of incidence and risk factors in NICU of Al-Minya University Hospital in Egypt. J Clin Neonatol. 2012;1(2):76–81. doi:10.4103/2249-4847.96755
  • Thomas K, Shah PS, Canning R, et al. Retinopathy of prematurity: risk factors and variability in Canadian neonatal intensive care units. J Neonatal Perinatal Med. 2015;8(3):207–214. doi:10.3233/NPM-15814128
  • Quinn GE, Johnson L, Abbasi S. Onset of retinopathy of prematurity as related to postnatal and postconceptional age. Br J Ophthalmol. 1992;76(5):284–288. doi:10.1136/bjo.76.5.284
  • Repka MX, Palmer EA, Tung B; For the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Involution of retinopathy of prematurity. Arch Ophthalmol. 2000;118(5):645–649. doi:10.1001/archopht.118.5.645
  • Sahinoglu-Keskek N, Akkoyun I, Torer B. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity. Eur J Ophthalmol. 2021;31(1):179–183. doi:10.1177/1120672119886989
  • Kuint J, Barak M, Morag I, et al. Early treated hypotension and outcome in very low birth weight infants. Neonatology. 2009;95(4):311–316. doi:10.1159/000180113
  • Mizoguchi M, Chu T, Murphy F, et al. Dopamine use is an indicator for the development of threshold retinopathy of prematurity. Br J Ophthalmol. 1999;83(4):425–428. doi:10.1136/bjo.83.4.425
  • Chen Z, Jia W, Kaufman PL, et al. Immunohistochemical localization of dopamine-beta-hydroxylase in human and monkey eyes. Curr Eye Res. 1999;18(1):39–48. doi:10.1076/ceyr.18.1.39.5391
  • Wu DM, Kawamura H, Li Q, et al. Dopamine activates ATP-sensitive K+ currents in rat retinal pericytes. Vis Neurosci. 2001;18(6):935. doi:10.1017/S0952523801186104
  • Allegaert K, Cossey V, Naulaers G, Vanhole C, Devlieger H, Casteels I. Dopamine is an indicator but not an independent risk factor for grade 3 retinopathy of prematurity in extreme low birthweight infants. Br J Ophthalmol. 2004;88(2):309–310. doi:10.1136/bjo.2003.025395
  • Kim SJ, Port AD, Swan R, Campbell JB, Chan RVP, Chiang MF. Retinopathy of prematurity: a review of risk factors and their clinical significance. Surv Ophthalmol. 2018;63(5):618–637.
  • Watts P, Adams GGW, Thomas RM, Bunce C. Intraventricular haemorrhage and stage 3 retinopathy of prematurity. Br J Ophthalmol. 2000;84(6):596–599. doi:10.1136/bjo.84.6.596
  • Waheeb S, Alshehri K. Incidence of retinopathy of prematurity at two tertiary centers in Jeddah, Saudi Arabia. Saudi J Ophthalmol. 2016;30(2):109–112. doi:10.1016/j.sjopt.2016.02.006
  • Yau GS, Lee JW, Tam VT, et al. Incidence and risk factors of retinopathy of prematurity from 2 neonatal intensive care units in a Hong Kong Chinese population. Asia Pac J Ophthalmol. 2016;5(3):185–191. doi:10.1097/APO.0000000000000167
  • Lundgren P, Lundberg L, Hellgren G, et al. Aggressive posterior retinopathy of prematurity is associated with multiple infectious episodes and thrombocytopenia. Neonatology. 2017;111(1):79–85. doi:10.1159/000448161